APTIOM Clinical Trials Overview1
• Three Phase 3 randomized, double-blind, placebo-controlled, trials established the effcacy of APTIOM as adjunctive treatment of partial-onset seizures. » Effcacy of APTIOM as an adjunctive treatment was established at both 800 mg/day and 1200 mg/day doses.
• These studies assessing treatment with APTIOM demonstrated signifcant reductions in standardized seizure frequency versus placebo, during 12-week maintenance phase (primary endpoint), and up to 41% of trial participants experienced a seizure reduction by 50% or more from baseline, compared to 21% placebo (secondary endpoint). Patients who did not achieve a 50% response may have achieved a range of responses, from slight worsening to less than 50% response.
• The most common adverse reactions (≥4% and ≥2% greater than placebo) were dizziness, sleepiness, nausea, headache, double vision, vomiting, feeling tired, problems with coordination, blurred vision and shakiness. Adverse reactions during titration were less frequent for adults who began therapy at an initial dose of 400 mg for one week and then increased to 800 mg compared to adults who initiated therapy at 800 mg. The rates of discontinuation as a result of any adverse event were 14% for the 800 mg dose, 25% for the 1200 mg dose, and 7% in subjects randomized to placebo.